Monday, September 14, 2020

Novus Therapeutics Acquires Anelixis Therapeutics

Irvine-based Novus Therapeutics, a developer of antibodies for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases, has acquired Anelixis Therapeutics, the company said on Monday. According to Novus Therapeutics, the acquisition was structured as a stock-for-stock transaciton, where all of Anelixis' outstanding equity interests were exchanged in a merger for a combination of shares of Novus common stock and shares of Preferred Stock. In conjunction with the merger, Novus Therapeutics said it has also entered into a PIPE investment with existing and new investors to raise approximately $108M.